Healthcare Providers and Services
Company Overview of Janssen Inc.
Janssen Inc. distributes healthcare products. The company offers products for mental wellness, anemia and fatigue, kidney disease, women’s health, wound healing, Alzheimer disease, eldercare, psychiatry, neurology, dementia, attention deficit hyperactivity disorder, immunology, pain management, gastroenterology, infectious diseases, and urology. It also offers oral medications for the treatment of HIV infection in combination with other antiretroviral agents. Janssen Inc. was formerly known as Janssen-Ortho Inc. The company was founded in 1941 and is based in Toronto, Canada with a division office in Montreal. Janssen Inc. operates as a subsidiary of Johnson & Johnson.
19 Green Belt Drive
Toronto, ON M3C 1L9
Founded in 1941
Key Executives for Janssen Inc.
Janssen Inc. does not have any Key Executives recorded.
Janssen Inc. Key Developments
Ontario Institute for Cancer Research Extends Collaboration with Janssen Inc. to Develop Clinical Trials for Prostate Cancer
Feb 25 15
The Ontario Institute for Cancer Research (OICR) is extending its collaborative research partnership with Janssen Inc. to develop more multi-centre clinical trials and other translational research projects that address important clinical questions in prostate cancer. The new funds will be made available to qualifying researchers at cancer centres across Canada who are addressing important clinical questions in prostate cancer. The funding will be dispersed to researchers through the Canadian Cancer Clinical Trials Network, which is based at OICR, through an open application process.
Janssen Inc. in Collaboration with USAID to Expand Access to Multidrug-Resistant TB Therapy
Dec 15 14
Janssen Inc. signed a memorandum of understanding with the US Agency for International Development (USAID) regarding the firm's commitment to tackle multidrug-resistant tuberculosis (MDR-TB). Based on the terms of the agreement, Janssen will provide approximately 30,000 courses of its MDR-TB drug Sirturo (bedaquiline), which is worth an estimated USD 30 million, to USAID that consequently will work with national TB programmes to provide access to the treatment using certain eligibility criteria.
Janssen Inc. Announces Availability of PREZCOBIX(TM) for Canadians Living with HIV
Sep 17 14
Janssen Inc. announced that PREZCOBIX(TM) (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. Patients with conditions like HIV that require either taking medication more than once a day or taking multiple medications may find it difficult to adhere to their treatment schedules. Research has shown that reducing the number of pills given to patients living with HIV can significantly improve adherence. PREZCOBIX(TM): A new option for the management of HIV PREZCOBIX(TM) is a fixed-dose combination tablet containing darunavir, a protease inhibitor currently marketed as PREZISTA(R), with a boosting agent called cobicistat, marketed as TYBOST(TM) by Gilead Sciences Inc. PREZCOBIX(TM) is approved in combination with other anti-retroviral agents for the treatment of HIV infection in treatment-naïve and treatment-experienced patients without darunavir resistance-associated mutations. PREZCOBIX(TM) received notice of compliance (NOC) from Health Canada on June 19, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|